Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma
Convertases and Pancreatic Cancer. New Therapeutic and Prognostic Approach: Cohort of Patients Treated for Pancreatic Adenocarcinoma (CONVERCAP)
Institut Bergonié
50 participants
Mar 27, 2026
OBSERVATIONAL
Conditions
Summary
This is a prospective, single-centre, observational study. The analysis of samples of pancreatic tumours and/or metastases taken during biopsy or surgery will lead to the determination of the level of expression of convertases in patients with pancreatic cancer and could be used as an additional prognostic means reinforcing those currently used.
Eligibility
Inclusion Criteria11
- Age ≥ 18 years.
- Pancreatic adenocarcinoma (suspected on radiological assessment or histologically proven):
- Indication for biopsy of metastasis(es) performed as part of standard care for patients who already have a histologically confirmed diagnosis of pancreatic cancer.
- Indication for pancreatic surgery or metastasis(es) carried out as part of standard care for patients with a suspicion of pancreatic cancer on radiological assessment or who already have a confirmed histological diagnosis of pancreatic cancer.
- Whatever the stage of the disease.
- Whatever the type of treatment proposed (systemic, surgery, radiotherapy, etc.).
- Patient who has never received systemic treatment or advanced radiotherapy.
- WHO 0-1-2.
- Life expectancy > 3 months.
- Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).
- Patient affiliated to a social security scheme in compliance with Article 1121-11 of the French Public Health Code.
Exclusion Criteria5
- Indication for biopsy for primary diagnosis of pancreatic cancer
- No indication for treatment of pancreatic cancer.
- Adjuvant/neoadjuvant chemotherapy completed less than 6 months ago in the case of patients with recurrent disease.
- Patient already included in the study.
- Geographical, social or psychological factors rendering the patient unable to undergo study monitoring and procedures.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
On the same day as the tumour sample is taken (biopsy or surgery), a blood sample of approximately 15 to 20 mL is taken in EDTA-free tubes.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06705335